BeOne Medicines, Ltd., a global oncology company, announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will increase BeOne's production capacity to manufacture its medicines and is expected to create approximately 120 new full-time jobs. The investment supports the continued advancement of BeOne's deep oncology pipeline of more than 35 clinical and commercial-stage assets.
Aaron Rosenberg, Chief Financial Officer, BeOne Medicines, said:
“Today's announcement reflects BeOne's commitment to strengthening U.S. manufacturing and expanding access to innovative medicines for patients with cancer. We appreciate the federal tax policies advanced by the President that encourage investment in biopharmaceutical production, alongside the Next New Jersey Manufacturing Program and the Governor’s efforts to support advanced manufacturing and high-quality job creation. Together, these efforts create an environment for long-term growth, and we are proud to continue expanding our global footprint in support of patients.”
Expansion highlights include:
- Total capital investment: $300 million, bringing total Hopewell investment to more than $1 billion
- New full-time positions: Approximately 120
- New construction: Approximately 145,000 square feet; expanded facility anticipated to be fully operational in 2029
- Total campus size post-expansion: Approximately 545,000 square feet
- Hopewell site headcount: Approximately 240 by the end of 2029